l-Asparaginase from Erwinia carotovora: insights about its stability and activity
- 42 Downloads
Enzymatic prospection indicated that l-asparaginase from Erwinia carotovora (ECAR-LANS) posses low glutaminase activity and much effort has been made to produce therapeutic ECAR-LANS. However, its low stability precludes its use in therapy. Herein, biochemical and biophysical assays provided data highlighting the influence of solubilization and storage into ECAR-LANS structure, stability, and activity. Moreover, innovations in recombinant expression and purification guaranteed the purification of functional tetramers. According to solubilization condition, the l-asparaginase activity and temperature of melting ranged up to 25–32%, respectively. CD spectra indicate the tendency of ECAR-LANS to instability and the influence of β-structures in activity. These results provide relevant information to guide formulations with prolonged action in the bloodstream.
Keywordsl-asparaginase Biophysical behavior In solution characterization
Funding was provided by Conselho Nacional de Desenvolvimento Científico e Tecnológico. Funding was provided by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior. Funding was provided by Fundação Oswaldo Cruz. Funding was provided by Programa de Pesquisa para o SUS.
Compliance with ethical standards
Research involving human and animal participants
This article does not contain any studies with human participants or animals performed by any of the authors.
- 2.Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Arkin S, Declerck L, Cohen HJ, Sallan SE (2001) Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 97:1211–1218CrossRefGoogle Scholar
- 3.Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, Katz J, Yu A, Laver J, Ravindranath Y, Kurtzberg J, Desai S, Camitta B, Murphy SB (1999) Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 13:335–342CrossRefGoogle Scholar
- 4.Abshire TC, Pollock BH, Billett AL, Bradley P, Buchanan GR (2000) Weekly polyethylene glycol conjugated l-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 96:1709–1715PubMedGoogle Scholar
- 6.Avramis VI, Tiwari PN (2006) Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomed 1:241–254Google Scholar
- 9.Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, Samson Y, Schorin M, Dalton VK, Lipshultz SE, Neuberg DS, Gelber RD, Cohen HJ, Sallan SE, Silverman LB (2007) Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109:896–904CrossRefGoogle Scholar